FIELD: medicine.
SUBSTANCE: means contains: riboflavin mononucleotide 1.0 wt %, hydroxypropylmethylcellulose 1.0 wt % and physiological solution on a phosphate buffered basis - the rest.
EFFECT: use of the invention ensures formation of a stable pre-corneal colour film of prolonged action due to the viscosity properties of the solution and the natural diffusion of riboflavin into the corneal stroma through defective epithelium sites, providing additional therapeutic activity of the active and auxiliary substances.
3 ex
Title | Year | Author | Number |
---|---|---|---|
PREPARATION FOR DIAGNOSING CORNEAL INJURIES AND DISEASES | 2014 |
|
RU2552318C1 |
OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 |
|
RU2646452C1 |
PREPARATION FOR DIAGNOSIS OF EYE CORNEA ILLNESS AND TRAUMA | 1995 |
|
RU2098089C1 |
PREPARATION FOR EYE CORNEA ILLNESS AND TRAUMA DIAGNOSIS | 1995 |
|
RU2097031C1 |
HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 |
|
RU2631604C1 |
PREPARATION FOR DIAGNOSIS OF DISEASES AND TRAUMAS OF EYE CORNEA | 1995 |
|
RU2142292C1 |
PREPARATION FOR DIAGNOSTICS OF EYE CORNEA INJURY | 2009 |
|
RU2404811C1 |
OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 |
|
RU2560669C1 |
METHOD FOR APPLICATION OF REMEDY OIL SOLUTION ON CORNEA | 0 |
|
SU1771734A1 |
METHOD OF TREATING KERATOCONUS STAGE I-II | 2022 |
|
RU2819801C2 |
Authors
Dates
2017-10-11—Published
2016-07-27—Filed